These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29461849)

  • 1. Claims-based risk model for first severe COPD exacerbation.
    Stanford RH; Nag A; Mapel DW; Lee TA; Rosiello R; Schatz M; Vekeman F; Gauthier-Loiselle M; Merrigan JFP; Duh MS
    Am J Manag Care; 2018 Feb; 24(2):e45-e53. PubMed ID: 29461849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data.
    Stanford RH; Nag A; Mapel DW; Lee TA; Rosiello R; Vekeman F; Gauthier-Loiselle M; Duh MS; Merrigan JF; Schatz M
    Ann Am Thorac Soc; 2016 Jul; 13(7):1067-75. PubMed ID: 27070274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External Validation of a COPD Risk Measure in a Commercial and Medicare Population: The COPD Treatment Ratio.
    Stanford RH; Lau MS; Li Y; Stemkowski S
    J Manag Care Spec Pharm; 2019 Jan; 25(1):58-69. PubMed ID: 30589629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.
    Yu AP; Yang H; Wu EQ; Setyawan J; Mocarski M; Blum S
    J Med Econ; 2011; 14(3):315-23. PubMed ID: 21500975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation and Assessment of the COPD Treatment Ratio as a Predictor of Severe Exacerbations.
    Stanford RH; Korrer S; Brekke L; Reinsch T; Bengtson LGS
    Chronic Obstr Pulm Dis; 2020 Jan; 7(1):38-48. PubMed ID: 31999901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis.
    Abudagga A; Sun SX; Tan H; Solem CT
    Int J Chron Obstruct Pulmon Dis; 2013; 8():175-85. PubMed ID: 23589684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COPD treatment ratio: a measure for improving COPD population health.
    Parikh MA; Burbage SC; Gabriel MH; Shirley BE; Campbell PJ
    Am J Manag Care; 2024 Sep; 30(9):e251-e257. PubMed ID: 39302258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A score to predict short-term risk of COPD exacerbations (SCOPEX).
    Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a predictive model to identify patients at risk of severe COPD exacerbations using administrative claims data.
    Annavarapu S; Goldfarb S; Gelb M; Moretz C; Renda A; Kaila S
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2121-2130. PubMed ID: 30022818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study.
    Adibi A; Sin DD; Safari A; Johnson KM; Aaron SD; FitzGerald JM; Sadatsafavi M
    Lancet Respir Med; 2020 Oct; 8(10):1013-1021. PubMed ID: 32178776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis.
    Fitch K; Iwasaki K; Pyenson B; Plauschinat C; Zhang J
    Curr Med Res Opin; 2011 Jul; 27(7):1425-9. PubMed ID: 21599554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
    Suh DC; Lau H; La HO; Choi IS; Geba GP
    Curr Med Res Opin; 2010 Feb; 26(2):297-306. PubMed ID: 19961283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of mild exacerbation on COPD symptoms in a Japanese cohort.
    Sato M; Chubachi S; Sasaki M; Haraguchi M; Kameyama N; Tsutsumi A; Takahashi S; Nakamura H; Asano K; Betsuyaku T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1269-78. PubMed ID: 27354785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care.
    Bell CF; Coutinho AD; Farrelly E; Lokhandwala T; Landsman-Blumberg P
    J Med Econ; 2018 Jun; 21(6):629-638. PubMed ID: 29577787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic impact of using inhaled corticosteroids without prior exacerbation among elderly patients with chronic obstructive pulmonary disorder.
    Chen S; Plauschinat CA; Wu N; Fraser K; Boulanger L
    J Med Econ; 2011; 14(4):458-62. PubMed ID: 21651427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting frequent COPD exacerbations using primary care data.
    Kerkhof M; Freeman D; Jones R; Chisholm A; Price DB;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2439-50. PubMed ID: 26609229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Burden of Illness Related to Chronic Obstructive Pulmonary Disease Exacerbations in Québec, Canada.
    Dang-Tan T; Zhang S; Tavares RV; Stutz M; Ismaila AS; Vaillancourt J; Corriveau D; Stanford RH; Lin X; Nadeau GA; Simidchiev A; Parsons D; Sampalis JS
    Can Respir J; 2017; 2017():8184915. PubMed ID: 28713217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COPD exacerbations associated with the modified Medical Research Council scale and COPD assessment test among Humana Medicare members.
    Pasquale MK; Xu Y; Baker CL; Zou KH; Teeter JG; Renda AM; Davis CC; Lee TC; Bobula J
    Int J Chron Obstruct Pulmon Dis; 2016; 11():111-21. PubMed ID: 26834468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.
    Kern DM; Davis J; Williams SA; Tunceli O; Wu B; Hollis S; Strange C; Trudo F
    Respir Res; 2015 Apr; 16(1):52. PubMed ID: 25899176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.